ARTICLE | Company News

Halozyme increases revenue guidance on BMS, Roche deals

September 14, 2017 10:21 PM UTC

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $2.80 (21%) to $15.98 and raised its 2017 revenue guidance on Thursday after announcing two separate licensing deals for its Enhanze drug-delivery technology with Bristol-Myers Squibb Co. (NYSE:BMY) and Roche (SIX:ROG; OTCQX:RHHBY).

The biotech now expects 2017 revenues to be in the range of $245-$260 million, up from previous guidance of $115-$130 million...